Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives $11.70 Consensus PT from Analysts

Cardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) has received an average recommendation of "Moderate Buy" from the six research firms that are covering the stock, Marketbeat reports. One analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $11.70.

CRDF has been the subject of several research analyst reports. LADENBURG THALM/SH SH initiated coverage on Cardiff Oncology in a research note on Tuesday. They set a "buy" rating and a $19.00 target price for the company. HC Wainwright increased their target price on Cardiff Oncology from $17.00 to $18.00 and gave the stock a "buy" rating in a research report on Friday, May 9th. Jefferies Financial Group began coverage on Cardiff Oncology in a research report on Tuesday, June 24th. They issued a "hold" rating and a $3.50 target price on the stock. Finally, William Blair reissued an "outperform" rating on shares of Cardiff Oncology in a report on Wednesday, June 18th.

Institutional Trading of Cardiff Oncology

Several institutional investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets acquired a new position in shares of Cardiff Oncology during the fourth quarter valued at $25,000. Ledgewood Wealth Advisors LLC bought a new stake in shares of Cardiff Oncology in the first quarter worth about $35,000. Belpointe Asset Management LLC bought a new stake in shares of Cardiff Oncology in the first quarter worth about $37,000. Castleview Partners LLC acquired a new position in shares of Cardiff Oncology during the first quarter worth about $45,000. Finally, ProShare Advisors LLC acquired a new position in shares of Cardiff Oncology during the fourth quarter worth about $50,000. Institutional investors and hedge funds own 16.29% of the company's stock.

Cardiff Oncology Price Performance

Shares of NASDAQ CRDF traded up $0.29 during trading on Tuesday, hitting $3.94. 2,122,061 shares of the company were exchanged, compared to its average volume of 1,205,931. The company has a market cap of $262.13 million, a price-to-earnings ratio of -4.28 and a beta of 1.52. Cardiff Oncology has a 1 year low of $2.01 and a 1 year high of $5.64. The firm's fifty day moving average price is $3.20 and its 200 day moving average price is $3.52.

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). Cardiff Oncology had a negative net margin of 8,308.50% and a negative return on equity of 76.45%. The firm had revenue of $0.11 million during the quarter, compared to analyst estimates of $0.09 million. On average, research analysts forecast that Cardiff Oncology will post -0.99 earnings per share for the current year.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.